Vaccitech has taken the decision not to proceed with season 2 of the current FLU007 (Invictus) study due to the changes recommended by the UK Government which directed the NHS to use FLUAD (adjuvanted TIV) vaccine in the 65 year old and over population in the 2018/19 seasonal influenza vaccination programme. The current FLU007 protocol recommends the use of licensed QIV alongside the Vaccitech vaccine, MVA-NP+M1 in this same age group.

 

Upon review of this change by both Vaccitech and Primary Care Clinical Trials Unit, Oxford University, the joint decision to not proceed with season 2 was taken based mainly upon the fact that we do not currently have the safety and immunological interaction data to continue co-administration.

 

Vaccitech and PC-CTU continues to collate data from season 1 and analysis of this will be published in due course.

 

The development of MVA-NP+M1 will continue unabated, developing both a challenge study and a field study in which virologic and symptom responses will be key endpoints, and testing MVA-NP+M1 with a wider variety of licensed influenza vaccines.

 

For further information, please contact enquiries@vaccitech.co.uk